Skip to main content

ivx

A collection of 1 post

ivx

Invion Limited (IVX) - Clinical-Stage Biotech Facing Critical Funding Challenges

Target: $0.14 | Outlook: NEGATIVE | Upside: -30%

· Ryan Lim